Analytical Paper 4

profileINeal
CoronavirusPandemicandCovax.pdf

Date: 14/04/2021 JRN205WI Section 22391718, TR 12:30-1:45 PM

Assignment: Analytical Paper 4 Student ID: 610006

Student Name: Hassan Almarzooq Instructor: Dr. Tait

Analytical Paper 4: Covax and Coronavirus Pandemic

The BBC reported on the vaccines against Covid-19 which has being shipped

across the world to help overcome the pandemic that has caused a lot of harm in the

economics of the whole world, I want to discuss the benefit of Covax that will

ensure all the countries regardless to the economic status receive the vaccines fairly.

Currently about 38 Million of the vaccine doses have been delivered to 98 countries.

There is hope to end this pandemic if there is equally distribution of the vaccines

across the world said the Health experts.

There is a great need to share the vaccine because it has destroyed many life

to a closer of two million people in the world, it was reported that many richer

countries have bought more Covid Jabs compared to the poor countries. (The

Lancet, 2021). Covex has a target of ensuring that more than 2 billion people will

receive the vaccines in less than a year, 92 from the poor countries and 98 from the

rich countries. This scheme is organized by the World Health Organization (WHO),

Global Vaccine Alliance (Gavi) and Coalition for Epidemic Preparedness

Innovation (Cepi).

Alice Tait
a year; 92
Alice Tait
This should be spelled out.
Alice Tait
Covid vaccines
Alice Tait
destroyed many lives (close to two million people worldwide), and it was reported that many richer...
Alice Tait
according to health experts.
Alice Tait
equal
Alice Tait
Alice Tait
Alice Tait
regardless of their
Alice Tait
This should be a period.
Alice Tait
that have begun shipping across

(Herzog, 2021). About $6 billion has been raised by Covax, which is not

enough and they wished to increase it with another $2 billion in order to meet the

2021 budget, some funds were received from the UK government which they gave

about $ 734 Million while the United State pledged $ 4 billion in December, The

first act for president Joe Biden in the office was to sign the United Nation to Covax.

President Emmanuel Macron from France has request the rich countries to send 5%

of their vaccines to poor nations.

Most vaccines which are been used in world, they are produced from the UK,

Russia, China, U,S, and Europe, rich nations have bought about 53% of the

vaccines while the poor countries have bought about 14%. According to WHO it

suggest that to end the Covid it will need about 70%of people in the world to be

vaccinated, if they could decide to vaccinate 2 billion people per year then it could

have taken many years to reach their target of 70% in the world, which has

estimated of about 7.8 billion people. The first 2 billion vaccines was to be given to

the front liners who include the health workers, elderly and vulnerable.

Consideration for door to door vaccine was to help reach the elderly without

exposing them to more risk.

Alice Tait
Need something to wrap your paper up here!
Alice Tait
were to
Alice Tait
Alice Tait
then it could take many years
Alice Tait
Alice Tait
Comma splice.
Alice Tait
Again, spacing.
Alice Tait
Alice Tait
Alice Tait
suggested
Alice Tait
Alice Tait
Alice Tait
which are being used in the world are produced in the U.K., Russia, China, U.S., and Europe. Most nations...
Alice Tait
Alice Tait
requested that the
Alice Tait
As his first act as president, Joe Biden signed the United Nations (do you mean the United States?) to Covax.
Alice Tait
Again, this should be a period.
Alice Tait
Alice Tait
Watch your extra spacing.
Alice Tait
Comma splice. Say, "budget, but some..."
Alice Tait
I believe you have an extra space here and this citation should go at the end of the previous sentence.

References

Herzog, L., Norheim, O., Emanuel, E. and McCoy, M., 2021. Covax must go beyond

proportional allocation of covid vaccines to ensure fair and equitable access. BMJ,

p.m4853.

The Lancet, 2021. Access to COVID-19 vaccines: looking beyond COVAX. The

Lancet, 397(10278), p.941.